Limited edition Meta Quest 3S Xbox bundle features custom Xbox-themed headset and controllers, offering cloud gaming as part ...

Nvidia reclaimed the title of the most valuable publicly traded company. The AI chipmaking giant led by CEO Jensen Huang surpassed Microsoft after its stock jumped 3% to close at $141.40 on Tuesday.

The existing console approach, currently available as Xbox Series X and Series S, will continue. So far, the consoles have been developed internally. But Microsoft also plans to release handheld ...

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, announced ...

Microsoft has quietly reinvented the Surface Laptop for 2025. It's smaller than its 13.8-inch Surface Laptop 7 predecessor (and hurray for the end of that confusing name), thanks to a 13-inch display.

Microsoft (MSFT -0.28%) first became the world's biggest company based on market cap in September 1998. It stayed No. 1 for less than 18 months before being dethroned. But the software giant has ...

Barclays and Microsoft confirm major Copilot deal Over 100,000 workers will get M365 Copilot licenses Microsoft is set to invest $80 billion into AI this year alone ...

Microsoft is laying off 305 people in Redmond, Wash., as part of a new round of cuts that follow a separate layoff last month impacting nearly 3% of its global workforce, or about 6,000 employees.

OpenAI reaches 3 million paying business users with 50% growth since February, launching new workplace AI tools including connectors and coding agents to compete with Microsoft.

As Nintendo had teased, Nvidia has now discussed the custom GPU powering the Nintendo Switch 2, although it failed to go into the level of detail tech enthusiasts were hoping for.

Microsoft .NET Aspire adds resource graph, publishers Publishers, now in preview, are a new type of integration that help developers package and deploy .NET Aspire apps to Docker Compose ...

Germany’s Merck KGaA is facing a big hole in its late-stage pipeline after multiple sclerosis (MS) candidate evobrutinib missed the mark in two phase 3 trials, spelling the end ...